CRISPR Therapeutics AG (CRSP) Net Cash Flow (2015 - 2026)

CRISPR Therapeutics AG has disclosed Net Cash Flow across 12 years of filings, most recently posting -$132.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 216.91% year-over-year to -$132.0 million; the TTM figure through Jun 2026 stood at $94.3 million (up 132.39% YoY), while the FY2025 annual figure was $49.2 million, up 153.91% from the prior year.
• Net Cash Flow came in at -$132.0 million for Q2 2026 at CRISPR Therapeutics AG, down from $72.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $317.9 million in Q1 2024 to a low of -$286.4 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$35.6 million, with a median of -$22.1 million recorded in 2022.
• Year-over-year, Net Cash Flow plunged 461.67% in 2022 and surged 3243.38% in 2023.
• Over 5 years, Net Cash Flow stood at -$286.4 million in 2022, then jumped by 51.61% to -$138.6 million in 2023, then jumped by 152.44% to $72.7 million in 2024, then dropped by 15.98% to $61.1 million in 2025, then tumbled by 316.14% to -$132.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$132.0 million in Q2 2026, $72.3 million in Q1 2026, and $61.1 million in Q4 2025.